Tablets featuring sitagliptin, a DPP-4 inhibitor, targeted at type 2 diabetes control. Manufactured by pharmaceutical companies and supplied via B2B channels to wholesalers, medical facilities, and dispensing pharmacies. Utilized by healthcare providers in primary care and specialty diabetes clinics.